Biomarker and Histopathology Evaluation of Patients with Recurrent Glioblastoma Treated with Galunisertib, Lomustine, or the Combination of Galunisertib and Lomustine

Galunisertib, a Transforming growth factor-βRI (TGF-βRI) kinase inhibitor, blocks TGF-β-mediated tumor growth in glioblastoma. In a three-arm study of galunisertib (300 mg/day) monotherapy (intermittent dosing; each cycle =14 days on/14 days off), lomustine monotherapy, and galunisertib plus lomustine therapy, baseline tumor tissue was evaluated to identify markers associated with tumor stage (e.g., histopathology, Ki67, glial fibrillary acidic protein) and TGF-β-related signaling (e.g., pSMAD2). Other pharmacodynamic assessments included chemokine, cytokine, and T cell subsets alterations. 158 patients were randomized to galunisertib plus lomustine (n = 79), galunisertib (n = 39) and placebo+lomustine (n = 40). In 127 of these patients, tissue was adequate for central pathology review and biomarker work. Isocitrate dehydrogenase (IDH1) negative glioblastoma patients with baseline pSMAD2+ in cytoplasm had median overall survival (OS) 9.5 months vs. 6.9 months for patients with no tumor pSMAD2 expression (p = 0.4574). Eight patients were IDH1 R132H+ and had a median OS of 10.4 months compared to 6.9 months for patients with negative IDH1 R132H (p = 0.5452). IDH1 status was associated with numerically higher plasma macrophage-derived chemokine (MDC/CCL22), higher whole blood FOXP3, and reduced tumor CD3+ T cell counts. Compared to the baseline, treatment with galunisertib monotherapy preserved CD4+ T cell counts, eosinophils, lymphocytes, and the CD4/CD8 ratio. The T-regulatory cell compartment was associated with better OS with MDC/CCL22 as a prominent prognostic marker.

[1]  G. Reifenberger,et al.  Limited role for transforming growth factor-β pathway activation-mediated escape from VEGF inhibition in murine glioma models. , 2016, Neuro-oncology.

[2]  A. Brandes,et al.  A Phase II randomized study of galunisertib monotherapy or galunisertib plus lomustine compared with lomustine monotherapy in patients with recurrent glioblastoma. , 2016, Neuro-oncology.

[3]  R. Kaaks,et al.  Treg-Mediated Immune Tolerance and the Risk of Solid Cancers: Findings From EPIC-Heidelberg. , 2015, Journal of the National Cancer Institute.

[4]  K. Kelsey,et al.  Serum macrophage‐derived chemokine/CCL22 levels are associated with glioma risk, CD4 T cell lymphopenia and survival time , 2015, International journal of cancer.

[5]  S. Estrem,et al.  Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway , 2015, Drug design, development and therapy.

[6]  M. Weller,et al.  Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma. , 2015, Neuro-oncology.

[7]  Steven J. M. Jones,et al.  Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. , 2015, The New England journal of medicine.

[8]  G. De Velasco,et al.  Brain perfusion and permeability in patients with advanced, refractory glioblastoma treated with lomustine and the transforming growth factor-β receptor I kinase inhibitor LY2157299 monohydrate. , 2015, Oncology letters.

[9]  M. Weller,et al.  Transforming growth factor-β pathway activity in glioblastoma , 2015, Oncotarget.

[10]  J. Baselga,et al.  First-in-Human Dose Study of the Novel Transforming Growth Factor-β Receptor I Kinase Inhibitor LY2157299 Monohydrate in Patients with Advanced Cancer and Glioma , 2014, Clinical Cancer Research.

[11]  G. Reifenberger,et al.  MGMT testing—the challenges for biomarker-based glioma treatment , 2014, Nature Reviews Neurology.

[12]  S. Pileri,et al.  A novel immunohistochemical classifier to distinguish Hodgkin lymphoma from ALK anaplastic large cell lymphoma , 2014, Modern Pathology.

[13]  J. Zimmer,et al.  Elevated CD3+ and CD8+ tumor-infiltrating immune cells correlate with prolonged survival in glioblastoma patients despite integrated immunosuppressive mechanisms in the tumor microenvironment and at the systemic level , 2013, Journal of Neuroimmunology.

[14]  Alex M. Fichtenholtz,et al.  Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing , 2013, Nature Biotechnology.

[15]  D. Wainwright,et al.  Targeting Tregs in Malignant Brain Cancer: Overcoming IDO , 2013, Front. Immunol..

[16]  S. Howng,et al.  Plasma levels of transforming growth factor-beta 1 before and after removal of low- and high-grade astrocytomas. , 2013, Cytokine.

[17]  Gelareh Zadeh,et al.  Glioblastoma, a Brief Review of History, Molecular Genetics, Animal Models and Novel Therapeutic Strategies , 2012, Archivum Immunologiae et Therapiae Experimentalis.

[18]  J. Graff,et al.  Abstract C201: The combination of the small molecule TGFβR1 inhibitor LY2157299 monohydrate with CCNU substantially blocks SMAD phosphorylation and significantly suppresses human glioblastoma xenograft growth. , 2011 .

[19]  M. Preusser,et al.  IDH testing in diagnostic neuropathology: review and practical guideline article invited by the Euro-CNS research committee. , 2011, Clinical neuropathology.

[20]  G. D. de Bock,et al.  The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis , 2011, British Journal of Cancer.

[21]  J. Baselga,et al.  TGF-β Receptor Inhibitors Target the CD44(high)/Id1(high) Glioma-Initiating Cell Population in Human Glioblastoma. , 2010, Cancer cell.

[22]  David García-Dorado,et al.  TGF-beta increases glioma-initiating cell self-renewal through the induction of LIF in human glioblastoma. , 2009, Cancer cell.

[23]  Joshua M. Korn,et al.  Comprehensive genomic characterization defines human glioblastoma genes and core pathways , 2008, Nature.

[24]  I. Türbachova,et al.  DNA demethylation in the human FOXP3 locus discriminates regulatory T cells from activated FOXP3+ conventional T cells , 2007, European journal of immunology.

[25]  B. Scheithauer,et al.  The 2007 WHO classification of tumours of the central nervous system , 2007, Acta Neuropathologica.

[26]  Alejandra Bruna,et al.  High TGFbeta-Smad activity confers poor prognosis in glioma patients and promotes cell proliferation depending on the methylation of the PDGF-B gene. , 2007, Cancer cell.

[27]  W. Curry,et al.  Focus on TILs: Prognostic significance of tumor infiltrating lymphocytes in human glioma. , 2007, Cancer immunity.

[28]  Z. Trajanoski,et al.  Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome , 2006, Science.

[29]  A. Friedman,et al.  Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma. , 2006, Cancer research.

[30]  Martin J. van den Bent,et al.  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.

[31]  M. Marques,et al.  Phase II study of docetaxel plus enoxaparin in chemotherapy-naive patients with metastatic non-small cell lung cancer: preliminary results. , 2003, Lung cancer.

[32]  A Rimner,et al.  Sublethal irradiation promotes migration and invasiveness of glioma cells: implications for radiotherapy of human glioblastoma. , 2001, Cancer research.

[33]  N. Sobol,et al.  Preliminary results , 2020, Asymptotic Analysis of Random Walks: Light-Tailed Distributions.